Lumito and Tethis complete proof-of-concept study demonstrating compatibility between Lumito’s UCNP imaging and Tethis’ SmartBioSurface® slides
Lumito AB (“Lumito”) and Tethis S.p.A. (“Tethis”) today announce the completion of an initial proof-of-concept study evaluating the technical compatibility between Lumito’s UCNP-based labelling and imaging technology and Tethis’ SmartBioSurface® slide platform designed for non-adherent cells. The study focused on assessing whether Lumito’s labelling and imaging approach can be applied to cells captured using Tethis’ […]
Lumito and Offspring Biosciences initiate pilot study to combine automated, standardised workflows with high‑sensitivity tissue analysis
Lumito AB (publ) (“Lumito” or the “Company”) and Offspring Biosciences Sweden AB (“Offspring Biosciences”) today announce the initiation of a pilot study. The purpose is to evaluate the integration of Lumito’s proprietary tissue labelling and high-sensitivity imaging platform within Offspring Biosciences’ automated analytical workflows based on Roche Ventana Discovery Ultra. The pilot study will commence […]
Analyst Group publishes equity research report on Lumito
As announced by Lumito AB (publ) (“Lumito” or the “Company”) on January 13, 2026, Analyst Group conducts equity research coverage of Lumito, commissioned by the Company. The coverage includes equity research with quarterly updates as well as analyst comments on reports and press releases. Today, Analyst Group has published its first report on the Company. […]
Lumito presents at Analyst Group’s and InFront Direkt Studios’ capital markets day
Lumito AB (publ) ("Lumito" or the "Company") will, on Wednesday, 11 March 2026, present the Company, current status and the way forward at a capital markets day arranged by Analyst Group together with InFront Direkt Studios. Capital markets dayDate and time: 11 March 2026, 9:00-13:00 (Lumito's presentation is at 10:20).Location: online, follow this link to […]
Lumito AB publishes year-end report 2025
Financial overviewFourth quarter 2025, 1 October – 31 DecemberNet sales amounted to 0 (79) KSEK.Result after taxes amounted to -11,244 (-15,476) KSEK.Earnings per share before and after dilution amounted to -0.01 (-0.06) SEK.Cash flow from operating activities amounted to -8,616 (-8,713) KSEK. Full year 2025, 1 January – 31 DecemberNet sales amounted to 0 (97) KSEK.Result […]
Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging
Lumito AB (publ) (“Lumito” or the “Company”) and Atlas Antibodies AB (“Atlas Antibodies”) today announce a strategic partnership aimed at accelerating innovation in tissue analysis and strengthening their respective positions in a growing global market. By combining Lumito’s proprietary high-sensitivity imaging technology with Atlas Antibodies’ extensively validated antibody portfolio, the collaboration is designed to create […]
Invitation to webinar in connection with Lumito AB’s year-end report for 2025
Lumito AB (publ) (“Lumito” or the “Company”) will publish its year-end report for 2025 on 20 February 2026. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:30 CET. During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction to Lumito and […]
Lumito initiates pilot project with leading professor in urological cancer research at Lund University
Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company is initiating a pilot project in collaboration with Professor Anders Bjartell, senior consultant and Professor of Urological Cancer Research at Lund University. The project aims to evaluate the Company’s technology for improved and earlier detection of lymph node metastases in prostate cancer, which […]
Lumito receives patent approval in India
Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company has been granted a patent in India relating to its technology for tissue analysis using upconverting nanoparticles. The patent has previously been granted in Europe and the United States and further strengthens Lumito’s international intellectual property protection. The granted patent protects the technology […]
Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit
Lumito AB (publ) (“Lumito” or the “Company”) today announces that two Swedish research customers have placed orders for the Company’s SCIZYS Erbium kit. The orders include the use of the Company’s Scan-as-a-Service offering and strengthen the Company’s position within the research segment. Both customers require the high sensitivity enabled by Lumito’s technology. The first order […]